IP Library Granted Patent US 10,125,120
Granted Patent B2
US 10,125,120 · App. 14/966,437 · Granted Nov 13, 2018

Benzocyanine compounds

Inventors: Greg Hermanson (Loves Park, IL); Peter T. Czerney (Weimar, DE); Surbhi Desai (Rockford, IL); Matthias S. Wenzel (Jena, DE); Boguslawa Dworecki (Rockford, IL); Frank G. Lehmann (Jena, DE); Marie Christine Nlend (Rockford, IL)
Assignees: Pierce Biotechnology, Inc.; Dyomics GmbH
C07D403/06C07D495/04C07H3/00C07H21/00C07K14/00C07K14/475C07K14/575C07K16/00G01N33/5308
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,125,120
App. No.
14/966,437
Granted
Nov 13, 2018
Kind
B2
Abstract

Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.

Claims (11)

1. A compound of general formula IIa

or general formula IIb

where

each of R 1 , R 2 , R 5 , and R 6 is the same or different and is selected from the group consisting of an aliphatic, heteroaliphatic, sulfoalkyl, and heteroaliphatic with terminal SO 3 ;

each of R 7 , R 8 , R 11 , R 12 , R 13 , and R 14 is the same or different and is selected from the group consisting of H, and SO 3 wherein at least one of R 7 , R 8 , R 11 , R 12 , R 13 and R 14 is SO 3 ;

X is selected from the group consisting of —OH, —SH, —NH 2 , —NH—NH 2 , —F, —Cl, —Br, I, —NHS (hydroxysuccinimidyl/sulfosuccinimidyl), —O-TFP (2,3,5,6-tetrafluorophenoxy), —O-STP (4-sulfo-2,3,5,6-tetrafluorophenoxy), —O-benzotriazole, -benzotriazole, —NR-L-OH, —NR-L-O-phosphoramidite, —NR-L-SH, —NR-L-NH 2 , —NR-L-NH—NH 2 , —NR-L-CO 2 H, —NR-L-CO—NHS, —NR-L-CO-STP, —NR-L-CO-TFP, —NR-L-CO-benzotriazole, —NR-L-CHO, —NR-L-maleimide, and —NR-L-NH—CO—CH2-I, where R is —H or an aliphatic or heteroaliphatic group;

L is selected from the group consisting of a divalent linear (—(CH 2 ) t —, t=0 to 15), crossed, or cyclic alkyl group optionally substituted by at least one oxygen atom and/or sulfur atom;

Kat is a number of Na + , K + , Ca 2+ , ammonia, or other cation(s) needed to compensate the negative charge brought by the cyanine;

m is an integer from 0 to 5 inclusive; o is an integer from 0 to 12 inclusive; and n is an integer from 1 to 3 inclusive; and Z is a CH 3 group.

2. The compound of claim 1 wherein each of R13 and R14 is sulfo.

3. The compound of claim 1 wherein each of R7, R8, R11, and R12 is sulfo.

Assignments (2)
MERGER Recorded Mar 11, 2026
From: PIERCE BIOTECHNOLOGY, INC.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 075052/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2016
From: HERMANSON, GREG; CZERNEY, PETER T.; WENZEL, MATTHIAS S.; LEHMANN, FRANK G.; DESAI, SURBHI; DWORECKI, BOGUSLAWA; NLEND, MARIE CHRISTINE
To: PIERCE BIOTECHNOLOGY, INC.; DYOMICS GMBH
Reel/Frame 037461/0117 →
Continuity (6)
Division 13571858 · Aug 10, 2012
Provisional Application 61607737 · Mar 7, 2012
Provisional Application 61604232 · Feb 28, 2012
Provisional Application 61524167 · Aug 16, 2011
Related Publication 20160176853A1 · Jun 23, 2016
Related Publication 20170158672A9 · Jun 8, 2017